Featured news from NHIVNA
HIV-related news from NAM
Long-acting NRTI shows promise for HIV treatment and PrEP
Liz Highleyman, 2017-08-02 10:20:00
A single oral dose of MK-8591, a long-acting antiretroviral
in a novel drug class, suppressed HIV for seven days in an early clinical
trial, and the drug also appears to protect monkeys from rectal infection with
an HIV-like virus, researchers reported at the 9th International
AIDS Society Conference on HIV Science (IAS 2017) last week in Paris.
Although modern antiretroviral therapy (ART) is
generally effective and well tolerated, having more drugs that work in
different ways offers more options for constructing individualized regimens,
especially for people with drug-resistant virus. Good adherence is key to
effective ART and pre-exposure prophylaxis (PrEP), and some
people may find it easier to take pills less often than once daily.
Randolph Matthews from Merck presented
findings from a phase 1b clinical study of the antiviral activity and tolerability of
single doses of MK-8591 over 7 to 10 days in people living with HIV.
MK-8591, also known as EFdA, is a
long-acting nucleoside reverse transcriptase translocation inhibitor (NRTTI)
that binds to the polymerase active site of HIV reverse transcriptase.
Researchers previously reported that MK-8591 was highly potent in animal and human
studies, with a single oral dose producing adequate intracellular drug
concentrations for more than a week in HIV-negative volunteers. The drug also
showed good distribution to rectal and vaginal tissues in monkeys, indicating
potential suitability for PrEP. A rodent study showed that an injected
formulation of MK-8591 might maintain adequate drug levels for six months or
The current open-label study enrolled
30 HIV-positive participants who had not yet started ART. Participants received
a single dose of MK-8591 at doses of 0.5mg, 1mg, 2mg, 10mg or 30mg. Blood
samples were collected regularly for up to 10 days to assess viral load and pharmacokinetics
of MK-8591 and its active metabolite MK-8591-triphosphate (MK-8591-TP).
A pharmacokinetic analysis showed that the MK-8591
"parent" drug had a half-life ranging from 2.3 to 56.8 hours, while
the triphosphate form had a half-life life of 78.5 to 128
Single doses of MK-8591
across the whole range of tested doses led to "rapid and robust"
viral load reductions of at least 1 log10, the researchers reported.
At 168 hours after administration, mean viral load declines ranged from 1.18
log10 using the 0.5mg dose to 1.57 log10 using the 30mg
dose. No common resistance mutations were detected in tested samples.
Treatment was generally safe
and well tolerated at all doses. Most participants experienced some
treatment-emergent symptoms, but there were no serious adverse events. The most
common drug-related adverse events were mild to moderate headache, diarrhoea
and skin rash. There was no apparent association between dose level and
frequency or severity of side effects.
potency, human pharmacokinetics, and physical properties of MK-8591 have the
potential to open new paradigms for extended duration HIV treatment and
prophylaxis approaches," the researchers concluded.